Leerink Swann Weighs in on Shire PLC’s Q3 2016 Earnings (SHPG)
Shire PLC (NASDAQ:SHPG) – Equities researchers at Leerink Swann decreased their Q3 2016 earnings estimates for shares of Shire PLC in a research report issued to clients and investors on Tuesday. Leerink Swann analyst J. Gerberry now anticipates that the firm will earn $3.27 per share for the quarter, down from their previous forecast of $3.40. Leerink Swann has a “Buy” rating on the stock. Leerink Swann also issued estimates for Shire PLC’s Q4 2016 earnings at $3.20 EPS, FY2017 earnings at $15.37 EPS, FY2018 earnings at $18.05 EPS and FY2019 earnings at $20.84 EPS.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. During the same period in the previous year, the firm posted $2.63 EPS. Shire PLC’s revenue was up 55.9% compared to the same quarter last year.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Shire PLC from a “hold” rating to a “buy” rating and set a $192.00 target price for the company in a research note on Wednesday, June 29th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Friday, July 15th. BTIG Research reiterated a “buy” rating and set a $230.00 target price on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Thursday, July 7th. Five analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. Shire PLC has a consensus rating of “Buy” and a consensus price target of $228.15.
Shire PLC (NASDAQ:SHPG) traded down 1.12% during midday trading on Wednesday, reaching $188.56. The company had a trading volume of 362,608 shares. The firm’s 50 day moving average is $194.55 and its 200 day moving average is $188.26. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The stock has a market capitalization of $56.16 billion, a PE ratio of 39.19 and a beta of 1.16.
The company also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were given a dividend of $0.139 per share. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 15.63%.
A number of hedge funds have recently made changes to their positions in SHPG. Jennison Associates LLC raised its stake in shares of Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock worth $1,526,765,000 after buying an additional 968,101 shares during the period. FMR LLC raised its position in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock worth $490,297,000 after buying an additional 1,237,100 shares during the period. Lone Pine Capital LLC bought a new position in shares of Shire PLC during the second quarter worth $465,566,000. Capital World Investors bought a new position in shares of Shire PLC during the second quarter worth $285,568,000. Finally, Vanguard Group Inc. bought a new position in shares of Shire PLC during the second quarter worth $278,421,000. Hedge funds and other institutional investors own 24.30% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.